Establishing Impurity Specifications for Antibiotics
Summary
FDA has published a draft guidance providing recommendations on establishing specifications for organic impurities in antibiotics manufactured by fermentation and semi-synthesis. The guidance applies to antibiotic drugs subject to approval under new drug applications (NDAs), abbreviated new drug applications (ANDAs), and associated type II drug substance drug master files (DMFs), as well as nonprescription antibiotic OTC monograph drugs. Comments may be submitted at any time via Regulations.gov under docket FDA-2025-D-6130.
“This guidance also applies to nonprescription antibiotic drugs, often referred to as over-the-counter (OTC) monograph drugs.”
About this source
GovPing monitors FDA Newly Added Guidance for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 7 changes logged to date.
What changed
FDA published a draft guidance document recommending how manufacturers should establish specifications for organic impurities in antibiotics produced via fermentation and semi-synthesis processes. The guidance covers antibiotic drugs approved under NDAs and ANDAs, associated type II drug substance DMFs, and nonprescription OTC monograph antibiotics. By clarifying effective control strategies, FDA intends to support development of high-quality antibiotic products and promote consistency in quality standards.
Pharmaceutical manufacturers producing antibiotic drugs through fermentation or semi-synthesis, whether under approved applications or OTC monographs, should monitor this guidance for eventual compliance implications. Quality assurance and regulatory affairs teams responsible for drug substance and drug product specifications should review the recommendations when the guidance is finalized and consider submitting comments during the open comment period.
Archived snapshot
Apr 17, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Search for FDA
Guidance Documents
Docket Number: FDA-2025-D-6130 Issued by: Guidance Issuing Office Center for Drug Evaluation and Research The Food and Drug Administration (FDA, Agency, or we) is announcing the availability of a draft guidance for industry entitled “Establishing Impurity Specifications for Antibiotics.” The draft guidance provides recommendations regarding the establishment of specifications for organic impurities in antibiotics manufactured by fermentation and semi-synthesis. This draft guidance applies to antibiotic drugs subject to approval under new drug applications (NDAs) and abbreviated new drug applications (ANDAs) and associated type II drug substance drug master files (DMFs) referenced in antibiotic NDAs and ANDAs. This guidance also applies to nonprescription antibiotic drugs, often referred to as over-the-counter (OTC) monograph drugs. By providing these recommendations, FDA intends to clarify effective control strategies, support the development of high-quality antibiotic products, and promote consistency in quality standards.
Submit Comments
Submit Comments Online You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))
If unable to submit comments online, please mail written comments to:
Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852
All written comments should be identified with this document's docket number: FDA-2025-D-6130.
- ## Content current as of:
04/17/2026
Regulated Product(s)
- Drugs
Topic(s)
- Pharmaceutical Quality
- Chemistry, Manufacturing, and Controls (CMC)
Mentioned entities
Related changes
Get daily alerts for FDA Newly Added Guidance
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from FDA.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when FDA Newly Added Guidance publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.